B A C K G R O U N D Description of the condition
Pneumonia is the largest cause of childhood mortality, accounting for 15% of all childhood deaths under five years (WHO 2015) , and 19% of all childhood deaths in low-income countries (Bryce 2005; Rudan 2008) . Pneumonia is diagnosed by the presence of either fast breathing or lower chest wall indrawing (WHO 2015) in children aged under five years. Presenting features in viral or bacterial pneumonia are similar, however wheezing is more common in children with viral pneumonia. Pneumonia can be prevented by immunising against Haemophilus influenzae type B (Hib), pneumococcus, measles and pertussis (whooping cough) (WHO 2015) . Nutrition including breastfeeding for the first six months of life plays a major role by boosting immunity against causative organisms of pneumonia (WHO 2015) . Good hygiene and clean indoor air also help in preventing pneumonia (WHO 2015) . Rudan 2013 identified five risk factors for pneumonia: malnutrition, low birth weight, nonexclusive breast feeding, solid fuel use and overcrowding. By 2010, pneumonia episodes for children aged under four years in low-and middle-income countries (LMICs) decreased by 25% over the past decade to about 0.22 episodes per child per year when exposure to the five risk factors decreased by 20% to 30% (Rudan 2013) . Therefore, any interventions that can improve child survival from pneumonia are important. According to the World Health Organization (WHO), zinc deficiency accounts for 13% of all lower respiratory tract infection (LRTIs) (WHO 2009 ). Acute LRTI is a leading cause of mortality among children aged under five years (Bryce 2005; Rudan 2008) , and which is responsible for nearly two million deaths annually, mainly in low-income countries.
Description of the intervention
In 2005, zinc intake was inadequate among 17.3% of the world's population; rates of zinc adequacy are lower in sub-Saharan Africa and South Asia (Wessells 2012). The World Bank described multiple factors such as low animal food intake, less bioavailability of dietary zinc, and zinc loss during events of diarrhoea (Bhutta 1999; Black 1998 ) that could potentially lead to zinc deficiency in lowincome settings (World Bank 2016) . The WHO estimated that zinc deficiency may be related to 800,000 deaths a year, with more than 50% occurring in children under five years of age. Children are more susceptible to zinc deficiency because of lower rates of intestinal absorption and from starting life with low body stores due to intrapartum under-nutrition (Krebs 2014). Mild-to-moderate zinc deficiency is associated with impaired physical growth, delayed sexual maturity, behavioural disturbances, anorexia, affected permeability of the intestinal tract and decreased immunocompetence as well as subclinical inflammation; moderate-to-severe deficiency can lead to diarrhoea; and severe deficiency produces dermatitis and alopecia (Krebs 2014) . There is evidence that preventative zinc supplementation reduces pneumonia morbidity (Bhutta 1999; Yakoob 2011) and is beneficial in reducing diarrhoeal episodes in children with acute and persistent diarrhoea (Bhandari 1994; Zinc Group 2000) . However, there is insufficient evidence to support preventive zinc supplementation or adjunctive zinc supplementation with antibiotics to reduce pneumonia-specific mortality (Haider 2011; Yakoob 2011) . Zinc supplements (zinc sulphate, zinc gluconate, zinc acetate) can be administered as tablets, syrup or powder. However, zinc supplements need to be administered with caution because excess levels may cause toxicity.
How the intervention might work
Zinc plays an important role in cell regeneration, immunity and growth (Krebs 2014; Shankar 1998) . Zinc deficiency decreases T-lymphocytes and T-helper, impairs macrophage function and reduced killer cells (Ibs 2003; Ravaglia 2000) , and adversely impacts innate immunity affecting interferon (IFN) gamma production, interleukin-2 (IL-2) and tumour necrosis factor-α (TNF-α) (Krebs 2014) . Zinc supplementation in children increases levels of complement in the blood that modulate the function of Tlymphocytes, T-helper, macrophages and neutrophils and hence improves the ability to fight infection. Zinc supplementation improves circulating levels of T-lymphocytes and other macrophages that enhance ability to fight infection (Fraker 1993) . Zinc is not stored in the body, but repletion is straightforward. Children with diarrhoea can become zinc deficient quickly. Furthermore, if zinc deficiency occurs during periods of growth, it can be conducive to growth faltering as is shown by a review that found correlation between dietary zinc inadequacy and stunting among children aged under four years (Krebs 2014; Wessells 2012) .
Why it is important to do this review
Bhutta 1999 showed that zinc was associated with a reduced incidence of pneumonia. Aggarwal 2007 included more recent studies, but included children aged between birth and 59 months who were given zinc supplements for at least a few months. Roth 2010 calculated the effect size by case definition of pneumonia, and included studies that administered zinc supplements to children aged between birth and 59 months. Yakoob 2011 focused on zinc supplementation for more than three months in children aged under five years and found evidence to support the positive impact of zinc supplementation on diarrhoeal and pneumonia morbidity and mortality to include it in the LiST tool. However Yakoob 2011 did not include low birth weight or small-for-gestational age infants, nor provide a specific case definition for pneumonia.
Similarly, a review by Bhutta 2013 of diarrhoea and pneumonia interventions reported a non-significant impact of preventive zinc supplementation on acute lower respiratory infection (ALRI)-related mortality. We investigated zinc supplementation for at least three months in children aged from two months to 59 months and conducted a meta-analysis of data published up to 2011. However, with new and upcoming trials, this review required updating.
O B J E C T I V E S
To evaluate the effectiveness of zinc supplementation in the prevention of pneumonia in children aged two to 59 months.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) evaluating supplementation of zinc for the prevention of pneumonia in children aged from two to 59 months. We included studies that defined an episode of pneumonia in the following ways.
1. Reported cough or difficulty in breathing with a respiratory rate above the WHO-defined age-specific values (respiratory rate of 50 breaths per minute or more for children aged two to 11 months, or respiratory rate of 40 breaths per minute or more for children aged 12 to 59 months), and either documented fever over 38°C or chest in-drawing (WHO 1990) .
2. A diagnosis of pneumonia based on chest examination by a physician.
3. A diagnosis of pneumonia based on a chest radiograph. We included trials published in languages other than English. Quasi-RCTs were not eligible for inclusion.
Types of participants
We included children aged from two months to 59 months.
Types of interventions
Oral supplement containing at least the USA's recommended daily allowance of zinc versus either an oral supplement without zinc or placebo. We excluded trials in which children were given additional supplements unless the co-interventions other than zinc were the same in both groups. The recommended daily allowance for infants is 5 mg of elemental zinc per day and 10 mg per day for children aged from one to five years (RDA 1989) . We included trials in which supplements were administered for at least three months and outcome surveillance was carried out for at least four weeks.
Types of outcome measures
Primary outcomes 1. Numbers of new episodes of pneumonia in children aged from two months to 59 months.
Secondary outcomes
1. Prevalence (number of cases of pneumonia at a given time per total days of observation) of pneumonia in children aged from two months to 59 months. Science (1985 to 21 October 2016 . Details of previous searches are presented in Appendix 1. We used the search strategy described in Appendix 2 to search MEDLINE and CENTRAL. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-and precisionmaximising version (2008 revision); Ovid format (Lefebvre 2011) . We adapted the search strategy to search Embase (Appendix 3), LILACS (Virtual Health Library) (Appendix 4), CINAHL (Appendix 5) and Web of Science (Appendix 6). We searched IM-SEAR using the search terms "pneumonia" and "zinc". We imposed no language or publication restrictions. Figure 1 illustrates the search and study selection processes. 
Search methods for identification of studies

Searching other resources
We searched the WHO ICTRP (www.who.int/ictrp) and ClinicalTrials.gov trials registries (latest search 8 July 2016). We also searched related conference proceedings for relevant abstracts. We also checked the reference lists of all trials identified.
Data collection and analysis
Selection of studies
Two review authors independently assessed all potential studies identified for inclusion. We resolved any disagreement through discussion, and if required, consulted the third review author.
Data extraction and management
We designed a data extraction form. Two review authors extracted data. We resolved discrepancies through discussion, and if required, we consulted the third review author. We entered data into Review Manager software (RevMan 2014) and checked for accuracy. There were no new studies identified for inclusion in this update.
Assessment of risk of bias in included studies
There were no new studies identified for inclusion for this update. For the 2010 version of this review (Lassi 2010), two review authors (ZSL, BAH) independently assessed risk of bias using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved any disagreement by discussion with the third review author (ZAB).
Measures of treatment effect
For dichotomous outcomes, we extracted the total number of participants for each group and numbers of participants experiencing an event. We used risk ratio (RR) and 95% confidence intervals (CIs) to describe effect sizes.
Unit of analysis issues
We carried out statistical analysis using RevMan 2014). Initially, we used fixed-effect inverse variance meta-analysis to combine data where trials examined the same intervention, and study populations and methods were judged sufficiently similar. Where we suspected clinical or methodological heterogeneity between studies sufficient to suggest that treatment effects may differ between trials, we conducted random-effects meta-analysis. When we identified substantial heterogeneity in a fixed-effect meta-analysis, we noted this and repeated the analysis using the random-effects method.
Dealing with missing data
We noted levels of attrition among included studies. As far as possible, we performed analyses on an intention-to-treat (ITT) basis. We attempted to include all participants randomised to each group in the analyses.
Assessment of heterogeneity
We measured heterogeneity among the trials by calculating the I² statistic, and Chi² P value. If the I² statistic exceeded 50%, and the Chi² P value was less than 0.1, we would have considered heterogeneity to be substantial. We did not find any heterogeneity; therefore, we did not attempt subgroup analyses based on differences in zinc dosage, participants' age, supplementation in healthy children compared with children recovering from an episode of illness, and pre-intervention zinc levels. However, we attempted to look for the differential effect of zinc supplementation on the case definition of ALRI.
Assessment of reporting biases
We aimed to assess reporting bias by comparing published study reports with study protocols. We planned to assess for the presence of publication bias by looking for funnel plot asymmetry; however, the low number of included studies meant this was not feasible.
Data synthesis
We carried out statistical analysis using RevMan 2014 software. In the absence of significant heterogeneity, we used the fixed-effect meta-analysis model for combining data.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis based on diagnosis of pneumonia.
Sensitivity analysis
We planned to carry out a sensitivity analysis to explore the effect of trial quality (assessed by concealment of allocation), by excluding studies with clearly inadequate allocation concealment. However, only two studies had adequate allocation concealment, therefore we did not run the sensitivity analysis.
R E S U L T S Description of studies
See Characteristics of included studies, Table 1 and Characteristics of excluded studies tables.
Results of the search
This is an update of a review previously published in 2010 (Lassi 2010) . The most recent search (to October 2016) did not identify any new studies for inclusion.
Included studies
We included six trials. These studies were from Bangladesh Penny 2004 conducted a randomised, double-blind, placebo-controlled community-based trial in Lima, Peru that involved 238 children with diarrhoea for more than 14 days who were aged from six to 36 months. Children were randomised to receive zinc alone, zinc plus vitamins or placebo for two weeks. Childrens' characteristics at baseline were similar except for sex and length-for-age Z scores. Brooks 2005 conducted a study in a low-income population in an urban setting of Dhaka, Bangladesh. The study included 1665 children aged from 60 days to 12 months who were randomly allocated to receive oral zinc (70 mg) or placebo once weekly. Children were assessed weekly in the children's homes. Children with suggestive respiratory disease or diarrhoea were referred to clinics where they were assessed and diagnoses made based on the WHO criteria. Bhandari 2002 included 2482 children aged six to 30 months who were from urban slums in New Delhi, India. Children received daily elemental zinc (10 mg for infants; 20 mg for older children) or placebo for four months. Both groups received single dose vitamin A (100,000 IU for infants and 200,000 IU for older children) at enrolment. Both groups were comparable on socio-demographic profile, anthropometry, child feeding practices, morbidity in the previous 24 hours, and plasma zinc concentration. Luabeya 2007 included children aged from four to six months from the KwaZulu-Natal Province of South Africa. Children were randomised to two intervention arms and one control arm. Children in the control arm received vitamin A only; in the first intervention arm they were given vitamin A plus zinc; and in the second intervention arm children received vitamin A, zinc and multiple micronutrients. Children received supplements until 24 months of age, thus each child received zinc supplements for 18 to 20 months. Among the participants, 32 children were born with HIV positive status, and 154 were born without HIV infection to HIV positive mothers. Groups differed on weight-for-length scores. The double-blind controlled trial by Sazawal 1998 was conducted in a low socioeconomic population of 609 children aged between six and 35 months in urban India. Children were assigned to zinc supplementation (n = 298) and placebo (n = 311) groups. Children in the treatment group received 10 mg elemental zinc and placebo group children received a substance similar in colour and taste. The daily fixed dose of 5 mL per child was given to all enrolled children for six months, but this was increased to 10 mL for children with diarrhoeal illnesses. The baseline characteristics of included children were similar for age, sex, nutritional status and baseline plasma zinc. Bobat 2005 conducted a randomised, double-blind, placebo-controlled equivalence trial of zinc supplementation at Grey's Hospital in Pietermaritzburg, South Africa. The study included 96 children aged from six to 60 months with HIV 1 infection who were randomly assigned to receive 10 mg of elemental zinc sulphate or placebo daily for six months. Baseline characteristics of included children were similar.
Excluded studies
We excluded 30 studies that did not satisfy inclusion criteria. Seven studies included children outside the age limits of our review criteria (Lira 1998; McDonald 2015; Osendarp 2002; Sur 2003; Taneja 2009; Tielsch 2007 (also reported a different response to intervention definition than we used); Vakili 2009). We excluded seven studies that provided supplements for less than three months (Baqui 2002; Castillo-Duran 1987; Chandyo 2010; Feiken 2014; Rahman 2001; Roy 1999; Sempértegui 1996) . We excluded 14 studies that applied different case definitions for ALRI/pneumonia, which were not based on WHO criteria, radiograph or chest examination by physician (Baqui 2003; Larson 2010; Long 2006; Lind 2004; Malik 2014; Mazoomar 2010; Ninh 1996; Reul 1997; Richard 2006; Sampaio 2013; Sanchez 2014; Soofi 2013; Rosado 1997; Umeta 2000) . We excluded one study because children received zinc supplement in a fortified drink (Bates 1993). We also excluded one study (Adhikari 2016) because it had included children with recurrent infections. Please refer to Characteristics of excluded studies for further details. 
Risk of bias in included studies
Other potential sources of bias
The funding agencies were reported to have had no input to design or study results in three studies ( 
Effects of interventions
See: Summary of findings for the main comparison Zinc supplementation compared with placebo for the prevention of pneumonia in children aged 2 months to 59 months All six studies reported the incidence of pneumonia (Bhandari 2002; Bobat 2005; Brooks 2005; Luabeya 2007; Penny 2004; Sazawal 1998) , while one study (Sazawal 1998) also reported prevalence rates.
Incidence of pneumonia
Administration of zinc supplementation showed a statistically significant impact on reducing pneumonia incidence by 13% (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.81 to 0.94, fixed-effect model, six studies, n = 5193, low-quality evidence). There was no heterogeneity (I² statistic = 28%, Chi² test P = 0.20; Analysis 1.1). We pooled studies that used similar case definitions. Studies that used clinical definitions of age-specific fast-breathing, with or without lower chest indrawing did not exhibit impact from zinc supplementation on reducing pneumonia (RR 0.95, 95% CI 0.86 to 1.06, fixed-effect model, four studies, n = 1932). There was no heterogeneity (I² statistic = 0%, Chi² test P = 0.74).
Studies that applied case definition for pneumonia based on chest examination or chest radiograph exhibited significant impact from zinc supplementation on reducing incidence of pneumonia by 21% (RR 0.79, 95% CI 0.71 to 0.88, fixed-effect model, four studies, n = 3261). There was no heterogeneity (I² statistic = 0%, Chi² test P = 0.44). Bobat 2005 included children with HIV. When this study was removed from the analysis there was no difference in results (RR 0.88, 95% CI 0.81 to 0.95, fixed-effect model, three studies, n = 3165). Evidence was low quality (Summary of findings for the main comparison).
Prevalence of pneumonia
Administration of zinc supplementation showed a statistically significant impact on reducing the pneumonia prevalence by 41% among children aged from two to 59 months (RR 0.59, 95% CI 0.35 to 0.99, fixed-effect model, one study, n = 609, low-quality evidence; Analysis 1.2). (Summary of findings for the main comparison).
D I S C U S S I O N Summary of main results
This is an update of a review first published in 2010 and included no new studies. Previous conclusions are unchanged. We included six randomised controlled trials (RCTs) evaluating the impact of zinc supplementation in children aged from two to 59 months. Our meta-analysis indicated that zinc supplementation led to reductions in the incidence of pneumonia by 13% and pneumonia prevalence by 41%. The greater overall reduction of pneumonia prevalence result is due to prevalence data originating from one study. We found that zinc reduced pneumonia incidence (defined by specific clinical criteria and confirmed by chest examination or chest radiograph) by 21%. We found an expected association of acute lower respiratory infection (ALRI) case definition with an effect size (P = 0.02). We found benefits of zinc supplementation when ALRI was diagnosed following clinical examination or chest radiography suggesting infection. Reduction in pneumonia incidence supports the use of zinc supplements among children two to 59 months of age. Because zinc is not stored in the body, adequate zinc needs to be available in daily diet (Sanstead 1995) . Children, particularly those from low-income countries who have inadequate intake of food that contains zinc (mainly foods of animal origin) should receive supplements to address deficiency.
Overall completeness and applicability of evidence
Our findings from can be extrapolated for children living in low-and middle-income countries because most included studies were from disadvantaged urban areas of low-income countries (Bangladesh, India, Peru, and South Africa). In two studies, either children or their mothers had HIV positive status (Bobat 2005; Luabeya 2007) . In most studies, children were excluded if they had co-morbidities such as tuberculosis, congenital heart disease, less than 60% median weight-for-age Z score, and nutritional oedema. Penny 2004 recruited children on their breastfeeding status. The use of consistent and accurate definitions of pneumonia, with emphasis on clinical documentation of key signs or radiographic diagnosis, would avoid misclassification and lead to greater confidence in study findings.
Quality of the evidence
We assessed that review outcomes were low according to GRADE criteria. We downgraded evidence quality because outcomes were ascertained using different criteria and 'Risk of bias' assessment. Of note, half of the included studies reported pneumonia according to the WHO definition (WHO 1990) ; the remainder relied on clinical examination and chest radiographs. We therefore looked for differential effects on outcome estimates with respect to case definition and reported their impact separately. Allocation concealment was adequately described overall. All included studies were deemed to be adequately blinded for treatment assignment. Completion rates were greater than 90% in four included studies; Penny 2004 reported completion by 16% of participants and Sazawal 1998 did not report numbers of participants who dropped out. The low levels of missing data meant that we chose not to assess the impact on overall estimates because it was not anticipated to cause significant bias in the study results.
Potential biases in the review process
We undertook a systematic search of the literature to identify all studies that met our inclusion criteria. Study selection and data extraction decisions were cross-checked independently by the review authors. Included studies were not free from bias; only one study was assessed at low risk of bias for all domains. We could not assess reporting bias because of the limited numbers of included studies.
Agreements and disagreements with other studies or reviews
We found RCT evidence from both high-and low-income countries showing an effect of zinc in decreasing morbidity and mortality in children due to respiratory and gastro-intestinal infections (Hambidge 1999; Sazawal 1998). The effect of zinc against infectious diseases is therapeutic as well as preventive. Findings reported by the Zinc Investigators' Collaborative Group in (Bhutta 1999) and Aggarwal 2007 were consistent with our review. Bhutta 1999 reported that children who received zinc supplements had positive effects for pneumonia (odds ratio (OR) 0.59, 95% CI 0.41 to 0.83). Moreover, Bhutta 1999 included trials that administered zinc supplements with therapeutic intent, which might have led to an overestimation of the potential preventive effects of zinc. Aggarwal 2007 included trials that recruited children aged from birth to 59 months who were provided zinc supplementation for at least three months; analysis showed 20% decreased incidence of respiratory illness among children supplemented with zinc compared with placebo. Similar findings were reported by Roth 2010 who also assessed specific case definitions for impact evaluation of children aged from birth to five years. Roth 2010 reported that zinc reduced ALRI incidence defined by specific clinical criteria (incidence rate ratio (IRR) 0.65, 95% CI 0.52 to 0.82), compared with no effect on lower-specificity ALRI case definitions based on caregiver reports (IRR 1.01, 95% CI 0.91 to 1.12) or WHO non-severe pneumonia (IRR 0.96, 95% CI 0.86 to 1.08).
A U T H O R S ' C O N C L U S I O N S Implications for practice
We found sufficient evidence to support the use of zinc supplementation for children aged from two to 59 months to prevent pneumonia. Our analysis supports use of preventive zinc supplementation to improve child health.
Implications for research
More well-designed, large-scale randomised controlled trials (RCTs) are needed to establish the benefit of zinc supplementation for preventing pneumonia among children aged from two to 59 months. Development of effective and feasible interventions to improve zinc status in children is essential. Enhancement of bioavailable zinc in foods by genetic engineering, plant breeding and periodical supplementation are other possible intervention strategies that should be evaluated.
Given the rising burden of child mortality due to respiratory infections, particularly pneumonia, and considering its decreasing impact with zinc supplementation, further reviews should be considered in which the effectiveness of zinc supplementation should be assessed for acute pneumonia provided that cases are well-defined by strict clinical criteria. 
A C K N O W L E D G E M E N T S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Bhandari 2002
Methods RCT in which the children were individually randomised by a computer-generated simple randomisation scheme in blocks of 8. Zinc or placebo bottles were labelled with a unique child identification number according to the randomisation scheme. Six bottles, one for each month and two extra, for each child were produced and labelled before enrolment commenced. The supplies for each child were kept separately in labelled plastic bags. The zinc and placebo syrups were similar in appearance, taste, and packaging. Blinding was maintained during analyses by coding the groups as A or B The study took place in the urban slum of Dakshinpuri in New Delhi, India. For episodes to be counted as individual, there had to be at least 14 intervening days. The children in the two groups were comparable for age, anthropometry, child feeding practices, morbidity in the previous 24 hours, socioeconomic characteristics and plasma zinc concentration
Participants
The study included children aged from 6 to 30 months. There were 1241 children in each group, and after dropouts, the number reduced to 1093 in the zinc and 1133 in the placebo groups. Children were excluded if consent was refused, were likely to move out of the study area within the next four months, needed urgent admission to hospital on the enrolment day or had received a massive dose of vitamin A (100,000 IU for infants and 200,000 IU for older children) within the two months before enrolment Selective reporting (reporting bias) Low risk We could not locate the protocol of this study. We could not find the trial registration number of the study. The outcomes mentioned in the methods were reported in the results
Other bias Low risk Sources of funding: funding agencies had no role in views and opinions mentioned in the study
Brooks 2005
Methods RCT in which random assignment to zinc or placebo was done with permuted blocks of variable length between 2 and 8. Placebo was designed to be identical to the zinc syrup in colour, odour, and taste. The study was conducted at Kamalapur, southeastern Dhaka, Bangladesh. The medical officer diagnosed pneumonia if crepitations were heard on inspiration with a respiratory rate greater than 50 breaths per minute; severe pneumonia was diagnosed if there was also chest indrawing, or at least one other danger sign Participants Children aged 60 days to 12 months at the time of enrolment and excluded those with known or suspected tuberculosis, chronic respiratory or congenital heart disease, or severe malnutrition requiring hospital admission. Pneumonia was diagnosed if crepitations were heard on inspiration with a respiratory rate greater than 50 breaths per minute; severe pneumonia was diagnosed if there was also chest indrawing, or at least one other danger sign. Children with wheezing or rhonchi with crepitations were also diagnosed with pneumonia. 809 children were randomly assigned to zinc and 812 to placebo. There were no significant differences between groups at baseline, except for a slightly higher proportion of boys in the zinc group. There was no difference between the groups in serum zinc values at baseline
Brooks 2005 (Continued)
Interventions Zinc was given orally as a syrup (35 mg zinc acetate per 5 mL). The placebo was nonnutritious and vitamin-free. Compliance required intake of two teaspoons of syrup (10 mL). Children with pneumonia were treated with co-trimoxazole (10 mg/kg trimethoprim, twice daily for 5 days) for pneumonia. Children on antibiotics were assessed within 72 hours of starting treatment; those who did not improve (i.e. the respiratory rate did not change by more than 5 breaths/minute from baseline) were switched to treatment with amoxicillin (40 mg/kg, three times daily for 5 days). If oral treatment failed, or if they had severe pneumonia, children were referred to hospital for parenteral treatment (ceftriaxone 75 mg/kg intramuscularly per day). Children with only expiratory wheezes or rhonchi were managed with salbutamol syrup (0.3 mg/kg, 3 times daily), or referred to hospital for danger signs Blinding of participants and personnel (performance bias) All outcomes Low risk Quote: "ACME Laboratories (Dhaka) prepared, labelled and masked the identity of both preparations. Both placebo and treatment were designed to be identical in colour, odour, and taste"; "identity of both the preparations were masked"
Blinding of outcome assessment (detection bias) All outcomes Low risk Quote: "Blinding of FRAs was not affected because a proportion of children in both zinc and placebo groups reacted to the taste such that the treatment could not be distinguished"
Incomplete outcome data (attrition bias) All outcomes
Low risk Loss to follow-up was 9.1%. Withdrawal from both groups was most commonly attributed to the child's reaction to the taste of the syrup, which sometimes resulted in regurgitation. Most of those who withdrew were young, primarily breast fed infants. The highest proportion (37·1%) of withdrawals for both groups occurred at age 2 months, with 77·1% younger than 6 months Selective reporting (reporting bias) Low risk We could not locate the protocol of this study. We could not find the trial registration number of the study. The outcomes mentioned in the methods were reported in the results
Other bias Low risk Study seems to be free from other biases; the funding sources had no role in the study design, data collection, data analysis, interpretation of results, or decision to publish this 
Luabeya 2007
Methods What was the study design?
The study was conducted in northern KwaZulu-Natal Province, South Africa. Children were enrolled into the study by nurses at five government primary health care clinics. Pneumonia by maternal report was considered to have occurred if there was a history of either fast breathing or chest in-drawing. Confirmed pneumonia was defined as an elevated respiratory rate at rest measured by the fieldworker using WHO/UNICEF Integrated Management of Childhood Illness guidelines Participants Add number of participants. Children eligible for study were 4 to 6 months old. Children were excluded from the study if they were: less than 60% of median weight-for-age using United States National Center for Health Statistics standards; had nutritional oedema; had received vitamin or micronutrient supplements in the previous month; had diarrhoea for more than seven days at the time of study enrolment; or were enrolled in another study of a clinical intervention. Confirmed pneumonia was defined as an elevated respiratory rate at rest measured by the fieldworker using WHO/UNICEF Integrated Management of Childhood Illness guidelines The sponsor for the study was the host institution, the Africa Centre for Health and Population Studies, which gave discretion in the investigative team in study design, data analysis, manuscript preparation, and decisions on manuscript submission and publication
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk Quote: "An allocation list was prepared using computer-generated random numbers and a block size of six"; assignment to the three treatment arms was done separately for three cohorts of children stratified by HIV status of child and mother: HIV-infected children and mothers; HIV-uninfected children of HIV-infected mothers; and HIV-uninfected children of HIV-uninfected mothers Allocation concealment (selection bias) Low risk Quote: "The manufacturer prepared numbered packs of tablets corresponding to the allocation list. Children enrolled in the study were assigned by a study physician to one of the three study cohorts after results of the HIV tests became available. The physician then allocated the next pack of tablets from the blocks assigned to that cohort to the participant"
Blinding of participants and personnel (performance bias) All outcomes Other bias Low risk Sources of funding: The sponsor for the study was the host institution, the Africa Centre for Health and Population Studies, which gave discretion in the investigative team in study design, data analysis, manuscript preparation, and decisions on manuscript submission and publication
Penny 2004
Methods This randomised, double-blind, placebo-controlled, community-based trial was carried out in Canto Grande, a shanty town on the outskirts of Lima, Peru. The study was carried out in two phases. During the first phase researchers evaluated the effect of zinc or multiple micronutrient supplementation on the recovery from persistent diarrhoea. During the second phase researchers assessed the effect of continued supplementation on morbidity from new infections during the following 6 months Participants 412 children aged 6 to 36 months with diarrhoea for 14 days were randomly assigned, after being stratified for breastfeeding status, to receive two weeks of daily supplementation with one of three indistinguishable supplements: placebo; 20 mg zinc daily as zinc gluconate (zinc group); or 20 mg zinc daily as zinc gluconate plus a mixture of other micronutrients, i.e. vitamins and minerals (zinc VM group). A subset of children consisting of the first 246 children enrolled who intended to remain in the study area subsequently received the same assigned supplement at one-half the initial daily dose (10 mg zinc daily) and continued under observation for a total of 6 months Interventions Supplements were supplied as individual doses of a dry micronutrient mixture with added sugar, colouring and flavouring agents, which were dissolved in clean water in participants' homes and provided as a liquid beverage under the supervision of study personnel on Monday through Friday and by parents or other caregivers during the weekends. There were two intervention arms, zinc plus vitamins and minerals who were given 10 mg of zinc supplementation along with different combinations of mineral and vitamins. Another interventional arm was given zinc 10 mg and the control group was not given any supplementation
Sazawal 1998
Methods Double-blind RCT in which the loss of follow-up was less than 2% The study was conducted in a low socioeconomic population of urban India Participants Children, 6 to 35 months of age, presenting to a community-based clinic for acute diarrhoea and before enrolment, a parent of the child was given an explanation of the study and written informed consent was obtained. The baseline characteristics for the child-periods included in the analysis were similar between the two groups. The zinc group had 298 participants and the placebo one had 311
Interventions Children were randomised to receive either zinc or placebo in a liquid preparation containing vitamins A (800 units), B1 (0.6 mg), B2 (0.5 mg), B6 (0.5 mg), D3 (100 IU)
, and E (3 mg) and niacinamide (10 mg); the zinc preparation contained zinc gluconate (10 mg elemental zinc). The liquid preparation 5 mL was given daily for 6 months to all enrolled children; during diarrhoeal illness this was increased to 10 mL to provide for excess zinc losses Outcomes Incidence and prevalence of ALRI. ALRI was diagnosed as using WHO criteria for respiratory disease episodes based on fast breathing alone ALRI was also defined as child having cough and at least one assessment documenting: a) an elevated respiratory rate more than the age-specific value on both 1-minute estimations; and b) a recorded temperature of more than 101°F or lower chest indrawing 
A D D I T I O N A L T A B L E S
C O N T R I B U T I O N S O F A U T H O R S
Zohra S Lassi (ZSL) entered data, created the comparisons, carried out the analysis and wrote the text of the review under the guidance of Dr Zulfiqar A Bhutta (ZAB). Anoosh Moin (AM) took part in screening results and updating the review.
D E C L A R A T I O N S O F I N T E R E S T
Zohra S Lassi: none known.
Anoosh Moin: none known.
Zulfiqar A Bhutta: none known.
S O U R C E S O F S U P P O R T Internal sources
• The Aga Khan University, Pakistan.
External sources
• No sources of support supplied
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We have added mandatory sections such as subgroup analysis and sensitivity analysis for this update.
I N D E X T E R M S Medical Subject Headings (MeSH)
Gluconates 
MeSH check words
Child, Preschool; Humans; Infant
